RanBP9 Antibody (YA5234)

Cat. No.: HY-P85542: Fiche technique User Guide for Antibodies
FAQs
Technical Support

RanBP9 Antibody (YA5234) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to RanBP9.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Size		Stock
50 μL		Obtenir un devis
100 μL		Obtenir un devis

* Veuillez sélectionner la quantité avant d'ajouter des articles.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Description

Description

RanBP9 Antibody (YA5234) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to RanBP9.

Host

Mouse

Clonality

Monoclonal

Masse moléculaire

Observed band size: 78 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human

SwissProt ID

Q96S59

Gene ID

10048 [NCBI]

Immunogen

Purified recombinant human RanBP9 protein fragments expressed in E.coli.

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:1000
ICC/IF ICC/IF: Immunocytochemistry/Immunofluorescence	1:300

Pureté	affinity chromatography.	Conjugation	Non-conjugated
Modification	Unmodified

Appearance

Liquid

Formulation

Supplied in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Livraison

Shipping with blue ice.

Background

Function：May act as scaffolding protein, and as adapter protein to couple membrane receptors to intracellular signaling pathways (Probable). Acts as a mediator of cell spreading and actin cytoskeleton rearrangement (PubMed:18710924). Core component of the CTLH E3 ubiquitin-protein ligase complex that selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1 (PubMed:29911972). May be involved in signaling of ITGB2/LFA-1 and other integrins (PubMed:14722085). Enhances HGF-MET signaling by recruiting Sos and activating the Ras pathway (PubMed:12147692). Enhances dihydrotestosterone-induced transactivation activity of AR, as well as dexamethasone-induced transactivation activity of NR3C1, but not affect estrogen-induced transactivation (PubMed:12361945, PubMed:18222118). Stabilizes TP73 isoform Alpha, probably by inhibiting its ubiquitination, and increases its proapoptotic activity (PubMed:15558019). Inhibits the kinase activity of DYRK1A and DYRK1B. Inhibits FMR1 binding to RNA

Subcellular Localization：Cytoplasm; Nucleus; Cell membrane; Peripheral membrane protein

Expression：
Tissue_specificity:This gene is widely expressed in all tissues of the body, with the highest expression levels in the testes, placenta, heart, and muscles, and the lowest expression levels in the lungs. In the brain, it is mainly expressed by neurons in the cortical gray matter, cerebellar granular layer, and Purkinje cells.

Isoforms & Post-Translational Modification：Q96S59 has 3 isomers: Q96S59-1: 77847 Da (predicted); Q96S59-2: 43064 Da (predicted); Q96S59-3: 55082 Da (predicted).
Phosphorylated in response to stress. Can be phosphorylated by the cleaved p110 form of CDC2L1 (p110C);Ubiquitinated. Polyubiquitination targets the protein for rapid degradation via the ubiquitin system. Can be deubiquitinated by USP11

Subunit：Part of a complex consisting of RANBP9, MKLN1 and GID8 (PubMed:12559565). Identified in the CTLH complex that contains GID4, RANBP9 and/or RANBP10, MKLN1, MAEA, RMND5A (or alternatively its paralog RMND5B), GID8, ARMC8, WDR26 and YPEL5 (PubMed:17467196, PubMed:29911972). Within this complex, MAEA, RMND5A (or alternatively its paralog RMND5B), GID8, WDR26, and RANBP9 and/or RANBP10 form the catalytic core, while GID4, MKLN1, ARMC8 and YPEL5 have ancillary roles (PubMed:29911972). Interacts with GTP-bound Ran, AR, CDC2L1/p110C, CALB1, S100A7, USP11, MKLN1, SOS1 or SOS2, GID8, and FMR1 (PubMed:11470507, PubMed:12084015, PubMed:12147692, PubMed:12361945, PubMed:12421467, PubMed:12684061, PubMed:14511641, PubMed:14684163, PubMed:15381419, PubMed:18710924, PubMed:9817760). Interacts with the Dyrk kinases HIPK2, DYRK1A, and DYRK1B (PubMed:12220523, PubMed:14500717). Interacts with TP73 isoform Alpha but not with TP53 (PubMed:15558019). Interacts with the HGF receptor MET and the integrins ITGB1 and ITGB2, but not with ITGAL (PubMed:14722085). Part of a complex consisting of RANBP9, RAN, DYRK1B and COPS5 (PubMed:14500717). Directly interacts with RANBP10 (PubMed:18222118). Interacts with YPEL5 (PubMed:20580816). Interacts with DDX4 (PubMed:27622290). Interacts with NGFR (By similarity). Interacts with TEX19 (By similarity)

Synonyms

B cell antigen receptor Ig beta associated protein 1; BPM 90; BPM L; BPM-L; BPM90; BPML; IBAP 1; Imp 9; Importin 9; Novel centrosomal protein RanBPM; RAN binding protein 9; Ran binding protein centrosomal; Ran Binding Protein in the Microtubule organizing center; Ran binding protein M; Ran BP9; Ran-binding protein 9; Ran-binding protein M; RANB9_HUMAN; RanBP 7; RANBP 9; RanBP7; RanBP9; RanBPM.

Documentation

User Guide for Antibodies (1077 KB)